Multiple Sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system (CNS), characterised by inflammatory infiltrates of T-cells, B cells, macrophages and focal demyelinating plaques within the CNS. Both Th1 and Th17 cell-mediated responses have been shown to play a role in the development of inflammatory demyelination. CD6 is an important cell surface protein predominantly expressed by human T cells and a subset of B cells, as well as by some B cell chronic lymphocytic leukemias and neurons. It has been shown that CD6 can function as an important accessory molecule in T cell activation. The present disclosure relates to a method and a use of a CD6 binding partner. In particular, the present disclosure relates to the use of an Itolizumab antibody specifically binding to Domain 1 (D1) of CD6 in the manufacture of a medicament for use in a subject having a stage of multiple sclerosis (MS) that exhibits increased levels of T helper 17 (Th17) cells and having an increased expression of IL-23R, wherein the use in the subject causes a reduction of Th17 cells and a reduction of TNF-alpha, IFN-gamma, IL-6, and IL-17A, and a reduction of expression of IL-23R on one or more of monocytes, T helper cells and natural killer cells in a body fluid of the subject.
Use of a cd6 binding partner and method based thereon